AMGN · News · 20260903N
Tavneos Regulatory Withdrawal Risk
AMGEN INC · 2026-09-03 · Importance 44 · Surprise 60 · In source text
UK regulators suspended Tavneos for new patients after identifying unreliable study data, creating a country-specific regulatory risk for Amgen. The suspension was cited repeatedly in third-party coverage as a headwind alongside otherwise positive pipeline developments. The reports do not quantify Tavneos revenue exposure or any potential charge associated with the action.
Key facts
- UK regulators suspended Tavneos for new patients due to unreliable study data. source
- Reports noted regulatory pressure on Tavneos and that this pressure is a negative risk factor for Amgen. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | UK regulators suspended Tavneos for new patients due to unreliable study data. |